Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 18;6(3):386-389.
doi: 10.1016/j.jaccao.2024.03.012. eCollection 2024 Jun.

Diversity in Cardio-Oncology Clinical Trials: JACC: CardioOncology How To

Yehoda M Martei  1   2 , Henrietta A Afari  3 , Carmen E Guerra  2   4
Affiliations
Review

Diversity in Cardio-Oncology Clinical Trials: JACC: CardioOncology How To

Yehoda M Martei et al. JACC CardioOncol. .

Abstract

•Intersectionality of health inequities in CVD and cancer may compound inequities in cardio-oncology.•Equitable access to clinical trials is 1 of many key strategies to mitigate these health disparities.•Cardio-oncology trials should collect and report the race and ethnicity of participants, including disaggregate data on smaller minority groups.•Successful interventions consist of multilevel strategies targeting structural-, clinical-, provider-, and patient-level barriers.

Keywords: disparities; health policy; outcomes; provider education.

PubMed Disclaimer

Conflict of interest statement

Dr Guerra has received grant support from the National Cancer Institute, Genentech, the Breast Cancer Research Foundation, the American Heart Association, and the Lazarex Cancer Foundation; serves as a member of the Advisory Board of Guardant Health; and has received honoraria from the National Comprehensive Cancer Network. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

References

    1. Chen S., Li J. Participation of Black US residents in clinical trials of 24 cardiovascular drugs granted FDA approval, 2006-2020. JAMA Netw Open. 2021;4(3) doi: 10.1001/JAMANETWORKOPEN.2021.2640. - DOI - PMC - PubMed
    1. Howie L.J., Scher N.S., Amiri-Kordestani L., et al. FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res. 2019;25(10):2949–2955. doi: 10.1158/1078-0432.CCR-18-3003. - DOI - PubMed
    1. Omland T., Heck S.L., Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. J Am Coll Cardiol CardioOnc. 2022;4(1):19–37. doi: 10.1016/J.JACCAO.2022.01.101. - DOI - PMC - PubMed
    1. Unger J.M., Vaidya R., Hershman D.L., Minasian L.M., Fleury M.E. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019;111(3):245. doi: 10.1093/JNCI/DJY221. - DOI - PMC - PubMed
    1. Enhancing the diversity of clinical trial populations-eligibility criteria, enrollment practices, and trial designs guidance for industry. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents...

LinkOut - more resources